Lupin receives USFDA approval for Iloperidone Tablets; Stock rises

9 May 2022 , 12:31 PM

Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), lloperidone Tablets, 1 mg, 2. mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to market a generic equivalent of Fanapt Tablets, 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg of Vanda Pharmaceuticals Inc.

The product will be manufactured at Lupin’s facility in Goa, India.

lloperidone Tablets (RLD Fanapt) had estimated annual sales of USO 162 million in the U.S. (IQVIA MAT March 2022).

At around 12:35 PM, Lupin was trading at Rs728.70 apiece up by Rs4.75 or 0.66% from its previous closing of Rs723.95 apiece on the BSE.